Content about Economy of Asia

April 9, 2013
Dr. Reddy's to move North America headquarters

Generic drug maker Dr. Reddy's Labs will move into a new North America headquarters and set up new laboratory space later this year, the company said Tuesday.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs will move into a new North America headquarters and set up new laboratory space later this year, the company said Tuesday.

The India-based company said it had entered into two lease agreements for a new headquarters and research-and-development center in Princeton, N.J. These include a 75,500-sq.-ft. office space at 107 College Rd East and a 31,000-sq.-ft. office and laboratory at 303 College Rd East.

April 2, 2013
Dr. Reddy's appoints new chairman, COO

Indian generic drug maker Dr. Reddy's Labs has appointed G.V. Prasad as chairman of the company, Dr. Reddy's said.

HYDERABAD, India — Indian generic drug maker Dr. Reddy's Labs has appointed G.V. Prasad as chairman of the company, Dr. Reddy's said Tuesday.

Prasad is currently vice chairman and CEO and will continue as chairman and CEO.

Meanwhile, Satish Reddy has been appointed vice chairman in addition to his current role as managing director and COO.

 

March 29, 2013
Dr. Reddy's launches generic acne drug

Dr. Reddy's has launched a drug for treating acne, the company said Friday.

HYDERABAD, India — Dr. Reddy's has launched a drug for treating acne, the company said Friday.

The Indian generic drug maker announced the launch of Zenatane (isotretinoin) capsules in the 20-mg and 40-mg strengths. The drug is a therapeutically equivalent generic version of Roche's Accutane. The Food and Drug Administration also approved the drug in the 10-mg strength.

Various versions of the drug had sales of about $309 million during the 12-month period that ended in January, according to IMS Health.

 

March 5, 2013
Dr. Reddy's launches generic cancer drug

Generic drug maker Dr. Reddy's Labs has launched a drug used to treat certain cancers, the company said Tuesday.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a drug used to treat certain cancers, the company said Tuesday.

Dr. Reddy's announced the launch of injectable zoledronic acid in the 4-mg-per-5-mL strength. The launch followed the Food and Drug Administration's approval of the drug.

The drug is a generic version of Novartis' Zometa. The drug is used to treat cancers that have spread to the bones and multiple myeloma.

CORRECTION: An earlier version of this story misstated the strength of the drug. The story has been corrected.

March 5, 2013
Ranbaxy to market antidepressant drug

Ranbaxy Labs will market a drug for depression under an agreement with another company, the drug maker said Tuesday.

PRINCETON, N.J. — Ranbaxy Labs will market a drug for depression under an agreement with another company, the drug maker said Tuesday.

Ranbaxy said it had entered an in-licensing agreement with Alembic Pharmaceuticals to market desvenlafaxine base extended-release tablets. Alembic is the sponsor of a new drug application filed with the Food and Drug Administration for the drug, which is bioequivalent to Pfizer's Pristiq. Pristiq had sales of $590 million during the 12-month period that ended in January.

January 25, 2013
Dr. Reddy's launches allergy drug

Dr. Reddy's has launched a drug used for treating allergies, the generic drug maker said Friday.

HYDERABAD, India — Dr. Reddy's Labs has launched a drug used for treating allergies, the generic drug maker said Friday.

The Indian drug maker announced the launch of desloratadine orally disintegrating tablets in the 2.5-mg and 5-mg strengths. The drug is a generic version of Merck's Clarinex Reditabs and is available in unit-dose packages of 30.

The branded version of the drug had sales of about $5.3 million during the 12-month period that ended in November 2012, according to IMS Health.

January 3, 2013
Dr. Reddy's launches hair-loss drug

Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

Dr. Reddy's announced the launch of finasteride tablets in the 1-mg strength, a generic version of Merck's Propecia. As the first company to successfully file for approval of a generic version of the drug, Dr. Reddy's is entitled to 180 days of market exclusivity in which to compete directly with the branded version.

Propecia had sales of about $136 million during the 12-month period that ended in October 2012, according to IMS Health.

November 28, 2012
Dr. Reddy's appoints new CFO, head of North America business

Dr. Reddy's Labs has appointed a new CFO and head of its North America business, the generic drug maker said.

HYDERABAD, India — Dr. Reddy's Labs has appointed a new CFO and head of its North America business, the generic drug maker said.

Dr. Reddy's said Umang Vohra will take over the role of EVP and head of generics for North America, starting in January 2013. Vohra has been CFO of Dr. Reddy's for the past four years.

Saumen Chakraborty will take over as CFO of Dr. Reddy's following Vohra's reappointment. Chakraborty is currently president and global head of quality, human resources, information technology and business process excellence.

November 27, 2012
Ranbaxy recalls several lots of generic Lipitor

Ranbaxy Labs has recalled more than three dozen lots of its generic version of a cholesterol-lowering statin drug due to the possible presence of foreign particles, the company said.

NEW YORK — Ranbaxy Labs has recalled more than three dozen lots of its generic version of a cholesterol-lowering statin drug due to the possible presence of foreign particles, the company said.

September 20, 2012
Dr. Reddy's launches antibiotic products

Drug maker Dr. Reddy's Labs has launched a generic antibiotic drug, the company said Thursday.

HYDERABAD, India — Drug maker Dr. Reddy's Labs has launched a generic antibiotic drug, the company said Thursday.

The India-based company announced the launch of amoxicillin tablets, capsules and oral suspension. The tablets are being launched in the 500-mg and 875-mg strengths, while the capsules are in the 250-mg and 500-mg strengths, and the oral suspension is in the 125-mg-, 200-mg-, 250-mg- and 400-mg-per-5-mL strengths.

October 14, 2010
Majority of Americans concerned about food prices, poll finds

A new poll conducted by the Financial Times and Harris Poll found that worry over...